A 37-year-old volunteer has become the first person to receive an experimental vaccine designed to protect against the Bundibugyo species of Ebola. Developed by researchers in Oxford using technology from the AstraZeneca Covid jab, the trial aims to establish the safety and immune response of the vaccine - a vital step toward preventing future outbreaks of this deadly virus.